• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Advances in Internal Medicine >Study of lipoprotein (α) in patients of acute coronary syndrome and effect of low dose nicotinic acid on its serum level
【24h】

Study of lipoprotein (α) in patients of acute coronary syndrome and effect of low dose nicotinic acid on its serum level

机译：急性冠脉综合征患者脂蛋白（α）的研究及低剂量烟酸对其血清水平的影响

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background and aims - Lipoprotein(a) is not an established independent risk factor. This study aims to observe whether lipoproteina(Lpa) is significantly high in patients of acute coronary syndrome (ACS) in comparison to healthy control. The second part of the study is aimed to know whether oral nicotinic acid treatment lowers Lpa level significantly. Methods - This is a prospective case control study with quasi-experimental design done on acute coronary cases admitted in our centre. Total 200 cases of ACS were included as cases and 46 healthy volunteers were controls. In later part of the study those patients who had high Lpa and were eligible were treated with nicotinic acid for 3 months and Lpa was measured again. Results - Mean Lp(a) level was 39.7mg/dl (±17) among the 200 ACS cases admitted in CCU with the maximum of 83 and minimum of 14. Among controls mean Lpa was 22mg/dl (±3.04) with maximum of 44 and minimum of 17mg/dl. Difference was significant with p value of < 0.01. It was observed that nobody discontinued the drug because of side-effects. In these patients there was significant reduction in serum Lpa level from 74.1mg/dl (± SD22.2) to 43.2mg/ dl (± SD21.9) p<0.01. Conclusion - The serum level of Lpa was significantly high in patients with ACS patients in comparison to control. This difference however was not significant between STEMI and NSTEMI patients. Low dose Nicotinic acid reduces Lpa significantly and is well tolerated by the patients. DOI: http://dx.doi.org/10.3126/jaim.v2i2.8778 Journal of Advances in Internal Medicine 2013;02(02):61-64
机译：背景和目的-脂蛋白（a）不是既定的独立危险因素。这项研究旨在观察与健康对照组相比，急性冠脉综合征（ACS）患者的脂蛋白（Lpa）是否显着高。该研究的第二部分旨在了解口服烟酸治疗是否能显着降低Lpa水平。方法-这是一项前瞻性病例对照研究，采用准实验设计，对我们中心收治的急性冠脉病例进行了研究。将总共​​200例ACS纳入病例，并以46名健康志愿者作为对照。在研究的后期，对那些具有高Lpa且符合条件的患者进行了烟酸治疗3个月，并再次测量了Lpa。结果-在CCU入院的200例ACS患者中，平均Lp（a）水平为39.7mg / dl（±17），最大为83和最小14。对照组中平均Lpa为22mg / dl（±3.04），最大为32mg / dl（±17）。 44和最低17mg / dl。差异显着，p值<0.01。据观察，没有人因为副作用而停药。这些患者的血清Lpa水平从74.1mg / dl（±SD22.2）显着降低至43.2mg / dl（±SD21.9）p <0.01。结论-ACS患者的Lpa血清水平明显高于对照组。然而，STEMI和NSTEMI患者之间的差异并不明显。低剂量烟酸可显着降低Lpa，并且患者可以很好地耐受。 DOI：http://dx.doi.org/10.3126/jaim.v2i2.8778内科学进展杂志2013; 02（02）：61-64

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号